tbuckley/cabot-search huggingface dataset:
Outcome of Patients with Chronic Myeloid Leukemia Who Recieved an Intermittent Imatinib Therapy.
Authors: Hyun-Gyung Goh, Soo-Hyun Kim, Jeong Lee, Sae-Eun Jang, Wan-Seok Kim, Yoo-Li Kim, Sa-Hee Park, Il-Young Kwon, Dong-Wook Kim
Journal: Blood (2007)
Rituximab Is the Essential Treatment Modality That Underlies the Significant Improvement in Short and Long Term Outcome of Patients with Advanced Stage Follicular Lymphoma - A 10 Year Analysis of GLSG Trials.
Authors: Wolfgang Hiddemann, Eva Hoster, Christian Buske, Martin Dreyling, Michael Kneba, Michael Hallek, Eva Lengfelder, Hannes Wandt, Michael Unterhalt
Journal: Blood (2006)
Reduced-Intensity Conditioning for Allogeneic Stem-Cell Transplantation (SCT) with Fludarabine and Intravenous Busulfan Is Associated with Improved Toxicity Profile and Longer Survival Than Conditioning with Fludarabine and Melphalan in Patients with Chemo-Sensitive Hematological Malignancies.
Authors: Avichai Shimoni, Izhar Hardan, Avital Rand, Noga Shem-Tov, Ronit Yerushalmi, Arnon Nagler
Journal: Blood (2007)
OP0235 Identification of Novel Cd4+ Lymphocyte Expression Quantitative Trait Loci in Untreated Early Arthritis Patients
Authors: A.G. Pratt, J. Massey, A.E. Anderson, N. Nair, J. Diboll, A. Skelton, D. Lendrem, L.N. Reynard, H.J. Cordell, S. Eyre, A. Barton, J.D. Isaacs
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Rheumatoid arthritis (RA) is a CD4+ lymphocyte-mediated disease of immune dysregulation. Genome-wide association scans (GWAS) have shown common variants at approximately 100 genetic loci to be associated with RA. However, the associated single nucleotide polymorphisms (SNPs) often lie in intergenic regions and the gene upon which they act has not been defined. Examining how RA-associated SNPs influence gene expression in relevant biological contexts will begin to address this. <h3>Objectives</h3> To map <i>cis</i> eQTLs at established RA risk loci in CD4+ lymphocytes of a well-characterised early arthritis cohort, and so gain insight into mechanisms of genetic risk. <h3>Methods</h3> Patients attending the Newcastle Early Arthritis Clinic, naïve to immunomodulatory therapy, donated high integrity RNA and DNA extracted from 98% pure CD4+ lymphocytes within 4 hours of blood draw. Detailed baseline and longitudinal clinical data were recorded for all participants, who were followed up for ≥1 year. Genotyping and global gene expression measurement was carried out using the Illumina Human CoreExome array, and either HT12v4 or WG6v3 BeadChip arrays, respectively, and expression data was batch-corrected and normalised using standard algorithms. Data were analysed using the R package. Variants in linkage disequilibrium (LD) with &gt;100 confirmed RA- SNPs<sup>1</sup> (r<sup>2</sup>&gt;0.8), and probes within 4MB of these LD blocks, were included in the analysis, seeking evidence of cis-eQTLs. <h3>Results</h3> Data from 249 white Caucasian early arthritis patients were available for analysis; diagnoses (confirmed at follow-up) were RA (n=88), spondyloarthropathy/other inflammatory arthritis (n=86), osteoarthritis/other non-inflammatory arthralgia (n=70) and undifferentiated arthritis. Analysis of 1,247 SNPs and 8,023 probes identified strong evidence for cis-eQTLs at a number of RA risk loci in this population overall (experiment-wide p&lt;0.05). Previously observed genes subject to eQTLs in primary human CD4+ lymphocytes replicated by our study include <i>BLK</i>, <i>FADS1</i> and <i>FADS2</i>. Genes whose expression specifically in these cells has, to our knowledge, been associated with RA risk variants for the first time include <i>RPS26</i>, <i>RNF167</i> and <i>IKZF3</i>. <h3>Conclusions</h3> We present the first detailed eQTL analysis in the pathophysiologically relevant setting of early arthritis CD4+ lymphocytes, free of confounding immunomodulatory treatment. Interactions of clinical parameters (including disease phenotype) with eQTL effects remains the subject of ongoing analyses, to be presented. Our findings have the potential to modify the biological candidate gene landscape of RA. <h3>References</h3> Okada Y et al. 2014 Nature. 506(7488):376–81 <h3>Disclosure of Interest</h3> None declared
Evaluation of Defibrotide (DF) in the Treatment of Hepatic Veno-Occlusive Disease (VOD) in Non-Stem Cell Transplant (non-SCT) Chemotherapy Patients (pts): Results From the Treatment IND (T-IND) Expanded Access Protocol and the Compassionate Use Program (CUP).
Authors: Paul G. Richardson, Brandon M. Triplett, Nancy A. Kernan, Stephan A. Grupp, Sally Arai, Paul R. Haut, Alfred P. Gillio, Elena Tudone, Marco Sardella, Valeria Bandiera, Carin Heringa, Leslie E. Lehmann, Robert J. Soiffer, Dietger Niederwieser
Journal: Blood (2012)
HLA Ligandome Profiling Identifies a Novel Category of Pathophysiologically Relevant CLL Associated Antigens
Authors: Daniel J. Kowalewski, Heiko Schuster, Claudia Berlin, Stefan Kahn, Linus Backert, Lothar Kanz, Helmut R. Salih, Hans-Georg Rammensee, Stefan Stevanovic, Juliane S. Stickel
Journal: Blood (2014)
Measurement of Thrombin Generation Is a Positive Predictive Biomarker of V enous Thromboembolism (VTE) in Metastatic Cancer Patients Enrolled in the Hypercan Study
Authors: Anna Falanga, Marina Marchetti, Cristina Verzeroli, Cinzia Giaccherini, Giovanna Masci, Armando Santoro, Filippo De Braud, Luigi Celio, Roberto Labianca, Mario Mandalà, Barbara Merelli, Carlo Tondini, Giampietro Gasparini, Roberta Sarmiento, Carmen Julia Tartari, Francesca Piras, Sara Gamba, Francesca Rio, Viola Milesi, Serena Tessarolo, Alfonso Vignoli, Laura Russo
Journal: Blood (2015)
PTU-039 Endoscopic Management of Complex Non Pedunculated Rectal Polyps
Authors: A Kurup, S Sen, S Hebbar
Journal: Gut (2016)

<h3>Introduction</h3> Complex NPRP (non pedunculated rectal polyp) is defined as the polyp which has an increased risk of malignancy, increased risk of incomplete resection/recurrence, increased risk of adverse event or SMSA level 4 polyp.<sup>1</sup> Complex rectal polyps are managed by endoscopic (EMR, ESD, hybrid ESD) techniques or by various surgical techniques (TEMS, TAMIS, TART, TASER), depending on the endoscopic lesion assessment and the local expertise. <h3>Methods</h3> The aim of this study was to describe the outcomes of the endoscopic management of complex rectal polyps in a large tertiary hospital (single operator). <h3>Results</h3> Over a period of 33 months (May 2013 to Jan 2016), 77 complex rectal polyps including 10 rectosigmoid polyps were encountered. The size of the polyp varied from 1 cm to 14 cms (median - 3.5 cm). The age of the patient varied from 50 to 92 (median age - 60). 29 polyps (37.6%) was confirmed to have cancer. The pre resection endoscopic accuracy of malignancy was 94%. Frank malignancy was suspected and confirmed in 7 cases and deemed not suitable for endoscopic resection. A small subpedunculated pT1 polyp cancer was resected enbloc, but was not suspected to be a cancer prior to resection.21 polyps were noted to have features suggestive of high risk of malignancy. All had attempted endoscopic resection, including EMR and/or hybrid ESD. Of these, 7 polyps was confirmed to have cancer. The surgery rate for complex rectal polyps (including lesions with endoscopic resections for cancer) is 4.2%. None of the benign polyps (including polyps with EMR/Hybrid ESD for recurrence at previous TEMS/EMR site, post surgery anastomosis site) had surgery. Of the data available for 54 polyps with post endoscopic resection, 46 polyps (85%) did not have any residual lesion at 3 months. Of the available data for 26 polyps at 12 months, no recurrence/residual lesion was noted. None of the resection had perforation. 2 polyp cancers had significant bleeding during attempted hybrid ESD and had surgical resection of the polyp cancer. Another benign polyp with hybrid ESD had significant bleeding controlled with haemospray. The average time of combined EMR/hybrid ESD procedures is 11.4 mins for every cm of polyp resected. Considering the age, co-morbidity, size, location and final histology, ESD or alternative micro surgical techniques would have made a difference to the final outcome in only one patient. <h3>Conclusion</h3> The pre resection endoscopic accuracy rate for malignancy is significantly high in a high volume centre. EMR and Hybrid ESD in experienced hands is an effective technique in managing complex rectal polyps. <h3>Reference</h3> 1 British Society of Gastroenterology/Association of Coloproctologists of Great Britain and Ireland guidelines for the management of large non-pedunculated colorectal polyps. <h3>Disclosure of Interest</h3> None Declared
Cervical Cancer Growth Is Regulated by a c-ABL–PLK1 Signaling Axis
Authors: Xu Yang, Gang Chen, Wei Li, Changmin Peng, Yue Zhu, Xiaoming Yang, Teng Li, Cheng Cao, Huadong Pei
Journal: Cancer Research (2016)

The nonreceptor tyrosine kinase c-ABL controls cell growth but its contributions in solid tumors are not fully understood. Here we report that the Polo-like kinase PLK1, an essential mitotic kinase regulator, is an important downstream effector of c-ABL in regulating the growth of cervical cancer. c-ABL interacted with and phosphorylated PLK1. Phosphorylation of PLK1 by c-ABL inhibited PLK1 ubiquitination and degradation and enhanced its activity, leading to cell-cycle progression and tumor growth. Both c-ABL and PLK1 were overexpressed in cervical carcinoma. Notably, PLK1 tyrosine phosphorylation correlated with patient survival in cervical cancer. In a murine xenograft model of human cervical cancer, combination treatment with c-ABL and PLK1 inhibitors yielded additive effects on tumor growth inhibition. Our findings highlight the c-ABL-PLK1 axis as a novel prognostic marker and treatment target for human cervical cancers. Cancer Res; 77(5); 1142-54. ©2016 AACR.
AB0156 Quantitative Proteomic Approaches for Identifying Urinary Biomarkers in Lupus Nephritis
Authors: V.G. Anania, M. Cascino, L.L. Dragone, C. Looney, J. Rae, P. Liu, W. Sandoval, T.R. Katsumoto, M. Neighbors, A. Morimoto, A.E. Herman, W.R. Mathews
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Lupus nephritis (LN) is a severe clinical manifestation of systemic lupus erythematosus (SLE) associated with significant morbidity and mortality. Assessment of severity and activity of renal involvement in SLE requires a kidney biopsy, an invasive procedure with limited prognostic value. Despite years of research, a need remains for proximal, non-invasive biomarkers to help inform treatment decisions and to monitor disease activity and progression. Recent retrospective studies have revealed that baseline urine protein-creatinine ratio (UPCR) and reduction in UPCR during induction therapy are significantly associated with renal outcome<sup>1</sup>. Although proteinuria is highly correlated with disease progression in LN, the composition of the urinary proteome of LN patients remains poorly characterized. <h3>Objectives</h3> To better characterize the urinary LN proteome, we performed a preliminary proteomics study comprised of three complimentary discovery proteomic methods to identify urinary biomarkers of LN. <h3>Methods</h3> Urine samples from three female patients with biopsy confirmed LN, high proteinuria (&gt;3 mg/mmol, and low serum complement C3 (&lt;80 mg/dL) were compared to age- and gender- matched healthy controls. These samples were profiled using three mass spectrometry-based methods: 2D SDS-PAGE fractionation, a chemical labeling approach using tandem mass tags, and a label free data-independent acquisition (DIA) method. <h3>Results</h3> Using these combined approaches &gt;2600 proteins were identified, 290 of which are up-regulated &gt;2-fold in LN samples compared to healthy controls. While the chemical labeling approach enabled identification of more total proteins (2,598 with chemical labeling vs. 919 with DIA, 1% False Discovery Rate), the DIA approach outperformed the chemical labeling approach in identification of proteins significantly up-regulated in LN samples (52 with chemical labeling vs. 173 with DIA). <h3>Conclusions</h3> These results suggest that DIA-based approaches are less biased towards high abundance analytes and therefore potentially more suitable for proteomic profiling of biological matrices with a broad dynamic range like urine. Furthermore, candidate biomarkers identified using the DIA method are easily adapted into a targeted, multiplexed mass spectrometry assay suitable for absolute quantitation of candidate biomarkers in a clinical trial. Results from this study will be used to inform longitudinal and interventional studies focused on understanding the biological implications of these candidate biomarkers and to direct development of novel tools to evaluate disease progression and treatment efficacy of current and future LN therapeutics. <h3>References</h3> Dall9Era et al. Lupus Sci Med. 2015. <h3>Disclosure of Interest</h3> None declared
Outcome, Prognostic Factors and Long-Term Follow-Up in 207 Chronic Phase CML Patients Receiving Front-Line Imatinib 400 mg at a Single Institution.
Authors: Hugues de Lavallade, Dragana Milojkovic, Jamshid S. Khorashad, Alistair Reid, Eduardo Olavarria, Jaspal Kaeda, John M. Goldman, Jane F. Apperley, David Marin
Journal: Blood (2007)
The Effect of Variation in Donor Platelet Function on Transfusion Outcome: A Semi-Randomised, Double Blind, Controlled Trial (PROmPT)
Authors: Anne M Kelly, Stephen F Garner, Nina Herbert, Thomas R Godec, Brennan C Kahan, Alison J Deary, Lekha Bakrania, Theodora Foukaneli, Charlotte A Llewelyn, Willem H. Ouwehand, Lorna W Williamson, Rebecca A Cardigan
Journal: Blood (2014)
Patterns of Infection in Patients with Myeloid Malignancies Receiving 5-Azacytidine: identification of Candidates for Antifungal Prophylaxis
Authors: Cristina Calderón, Jose F Falantes, Francisco Márquez-Malaver, Jose González, Maria Luz Martino, Isabel Montero, Ildefonso Espigado, Jose Antonio Pérez-Simón
Journal: Blood (2012)
AB0569 Does The Age at Disease Onset Influence The Clinical Presentation and Long-Term Outcome of Anca-Associated Vasculitides? Results from A Single-Centre Cohort: Table 1.
Authors: S. Monti, S. Balduzzi, L. Cavagna, C. Montecucco, R. Caporali
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> ANCA associated vasculitides (AAV) are a group of diseases that can transversally affect all age groups (1). <h3>Objectives</h3> To identify peculiar characteristics in clinical presentation and long-term outcome of patients with AAV according to age at diagnosis. <h3>Methods</h3> Medical records of patients followed at our Department up to December 2015 with a diagnosis of AAV were analysed. Patients were stratified according to age at diagnosis &lt;65 or ≥65 years old. <h3>Results</h3> A total of 96 patients with AAV were identified. General characteristics of the study population are presented in table 1. 72.91% of patients were diagnosed before the age of 65 (group A), while 27.09% presented with an elderly-onset disease (group B). Mean age at symptoms onset was 43.09±12.55 and 68.49±8.03, respectively (p&lt;0.0001). Mean follow up was 70.19±73.41 without significant differences between the two groups. The diagnosis of granulomatosis with polyangiitis (GPA) was more frequent in group A (33.33% Vs 9.37%; p=0.03). Accordingly, c-ANCA (PR3) were significantly more detectable in group A (p=0.03). Eosinophilic granulomatosis with polyangiitis (EGPA) and microscopic polyangiitis (MPA) were more represented in group A without reaching statistical significance. The clinical presentation at disease onset was characterised by a higher rate of ocular and musculoskeletal involvement in group A (p=0.004) and more frequent systemic symptoms (p=0.01) and peripheral nervous system involvement (p=0.008) in group B. A compromised renal function due to the vasculitic process was more reported in the elderly-onset group (p=0.007). Comorbidities were more relevant in group B (p&lt;0.0001). Treatment approach did not differ between the two groups, except for a lower mean corticosteroid (CS) dosage in the elderly group at induction, counterbalanced by a lower rate of CS suspension at the end of follow up. Rituximab was only prescribed to 3 female patients of group A. Despite the different organ involvement, indices of disease activity, prognosis and damage did not differ between the two groups. Outcome was generally favorable in both groups, with a 2% mortality rate in group B. <h3>Conclusions</h3> Elderly-onset AAV shows some peculiar characteristics of organ involvement at disease onset, a higher rate of comorbidities, and slightly different therapeutic approach compared to younger-onset patients; nevertheless, long-term outcome is generally equally favorable. <h3>References</h3> Scott DG, Watts RA. Epidemiology and clinical features of systemic vasculitis. Clin Exp Nephrol 2013;17:607–10. <h3>Disclosure of Interest</h3> None declared
Immunoglobulin M Heavy/Light Chain Pair Measurement Independently Predicts Clinical Outcome and Refines Prognostic Information Provided By Interim PET in Patients with Aggressive Lymphomas
Authors: Patricia Johansson, Jan Dürig, Jan Rekowski, Stefan P Müller, Bernd Hertenstein, Christiane Franzius, Frank Kroschinsky, Jörg Kotzerke, Rolf Mesters, Matthias Weckesser, Paul La Rosée, Martin Freesmeyer, Stefan Wilop, Thomas Krohn, Ulrich Dührsen, Andreas Hüttmann
Journal: Blood (2015)
Mitochondrial Dysfunction and Myocardial Ischemia-Reperfusion: Implications for Novel Therapies
Authors: Edward J. Lesnefsky, Qun Chen, Bernard Tandler, Charles L. Hoppel
Journal: The Annual Review of Pharmacology and Toxicology (2016)

Mitochondria have emerged as key participants in and regulators of myocardial injury during ischemia and reperfusion. This review examines the sites of damage to cardiac mitochondria during ischemia and focuses on the impact of these defects. The concept that mitochondrial damage during ischemia leads to cardiac injury during reperfusion is addressed. The mechanisms that translate ischemic mitochondrial injury into cellular damage, during both ischemia and early reperfusion, are examined. Next, we discuss strategies that modulate and counteract these mechanisms of mitochondrial-driven injury. The new concept that mitochondria are not merely stochastic sites of oxidative and calcium-mediated injury but that they activate cellular responses of mitochondrial remodeling and cellular reactions that modulate the balance between cell death and recovery is reviewed, and the therapeutic implications of this concept are discussed.
Platelet Production Occurs Independently of Both the Intrinsic and Extrinsic Apoptosis Pathways
Authors: Emma C. Josefsson, Deborah L. Burnett, Marlyse A. Debrincat, Katya J. Henley, Rachael M. Lane, Marion Lebois, Lorraine A. O'Reilly, Marc Pellegrini, Simon P. Preston, Ben A. Croker, Donald Metcalf, Andreas Strasser, Benjamin T. Kile
Journal: Blood (2012)
Secondary Acute Myeloid Leukemia and Myelodysplastic Syndromes Following ATRA and Anthracycline Monochemotherapy Treatment for Acute Promyelocytic Leukemia.
Authors: Pau Montesinos, Jose D. Gonzalez, Chelo Rayon, Javier de la Serna, Juan Bergua, Jordi Esteve, Mar Tormo, Edo Vellenga, Elena Amutio, Guillermo Deben, Miguel Sanz
Journal: Blood (2007)
A Distinct Entity of Ocular Adnexal MALT Lymphoma with Trisomy 18.
Authors: Kazuki Tanimoto, Naohiro Sekiguchi, Yukiko Yokota, Akihiro Kaneko, Shigenobu Suzuki, Dai Maruyama, Song-Wong Kim, Takashi Watanabe, Akiko Maeshima, Yoshihiro Matsuno, Kensei Tobinai, Yukio Kobayashi
Journal: Blood (2005)
Recent Advances in Photoacoustic Imaging for Deep-Tissue Biomedical Applications
Authors: Sheng Wang, Jing Lin, Tianfu Wang, Xiaoyuan Chen, Peng Huang
Journal: Theranostics (2016)

Photoacoustic imaging (PAI), a novel imaging modality based on photoacoustic effect, shows great promise in biomedical applications. By converting pulsed laser excitation into ultrasonic emission, PAI combines the advantages of optical imaging and ultrasound imaging, which benefits rich contrast, high resolution and deep tissue penetration. In this paper, we introduced recent advances of contrast agents, applications, and signal enhancement strategies for PAI. The PA contrast agents were categorized by their components, mainly including inorganic and organic PA contrast agents. The applications of PAI were summarized as follows: deep tumor imaging, therapeutic responses monitoring, metabolic imaging, pH detection, enzyme detection, reactive oxygen species (ROS) detection, metal ions detection, and so on. The enhancement strategies of PA signals were highlighted. In the end, we elaborated on the challenges and provided perspectives of PAI for deep-tissue biomedical applications.
Peripheral Blood Stem Cell Harvests Performed Beyond the Initial Two Days of Apheresis May Not Contribute to Accelerate Granulocyte and Platelet Engraftment After Autologous Stem Cell Transplantation.
Authors: Luciano Wannesson, Lisa Wang, John Kuruvilla, Tracy Nagy, Ronnie Saragosa, Norman Franke, Armand Keating, Michael Crump
Journal: Blood (2009)
FRI0279 Current Immunosuppressive Drugs Are Not Enough To Treat The Pulmonary Involvement of Connective Tissue Diseases
Authors: V. Yazisiz, S. Oygen, F. Erbasan, G. Arslan, E. Gökalp, G. Tazegül, A.B. Avci, E. Terzioğlu
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Interstitial lung diseases (ILDs) may occur secondary to connective tissue diseases (CTDs) and increase morbidity and mortality due to ventilation impairment. <h3>Objectives</h3> To reveal clinical, laboratory and imaging features of CTD -ILDs and to analyze treatment approaches. <h3>Methods</h3> One hundred thirty two consecutive patients were included in this cohort. Demographic characteristics, laboratory and HRCT results and treatment results were analyzed. More than 10% increase of pulmonary function tests were categorized as improvement, &gt;10% decrease were categorized as deterioration and ±10% changes were categorized as stable disease. <h3>Results</h3> There were 111 ILD patients (86.5% CTD-ILD) with follow-up time for more than 6 months. Median follow up time was 48 (Min-Max:6–260) months and mean age was 54.5±11.9 years. HRCT scan was repeated in median 3 (1–10) times per patients, with median 12.5 month intervals. The most frequent HRCT findings were ground-glass opacities, interlobular septal thickening and honeycomb patterns. 89.6% of CTD-ILD patients recieved corticosteroids and 44.8% recieved hydroxylchloroquine sulphate. Azathioprine and cyclophosphamide were the most common used immunosupresive drugs. Eighty four patients recieved at least one immunosuppressive agent. There were only 2 patients treated with four different immunosuppressive drugs. After treatment, mean pulmonary function tests did not significanty differ from baseline (p&gt;0.05) (Table). 35% of the patients improved <i>forced vital capacity</i>(FVC &gt;%10 increase) by treatment whereas 31% had decreased and 34% were stable. <h3>Conclusions</h3> It is not detected to have significant improvement by current immunosuppressive drugs in patients with CTD-ILDs. There is need more effective novel drugs to treat for CTD-ILD. <h3>Disclosure of Interest</h3> None declared
Pomalidomide (Pom) Dexamethasone (D) With Or Without Oral Weekly Cyclophosphamide (Cy) For Lenalidomide Refractory Multiple Myeloma (LRMM): A Multicenter Randomized Phase II Trial
Authors: Rachid Baz, Thomas G Martin, Melissa Alsina, Kenneth H. Shain, Hearn J. Cho, Jeffrey L Wolf, Anuj Mahindra, Ajai Chari, Daniel Sullivan, Lisa A Nardelli, Ccrp Ccrp, Kenneth Lau, Hui-Yi Lin, Sundar Jagannath
Journal: Blood (2013)
In Vivo T Cell Depletion with Thymoglobulin or Alemtuzumab Is Associated with Worse Outcome Following Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia Patients Transplanted in Remission
Authors: Scott R. Solomon, Melissa Sanacore, Xu Zhang, Katelin Connor, Melhem Solh, Lawrence E. Morris, H. Kent Holland, Asad Bashey
Journal: Blood (2015)